Oral contraceptives and venous thromboembolism: A systematic review and meta-analysis

Drug Safety

Volumn 35, Issue 3, 2012, Pages 191-205

  Manzoli, Lamberto ^a   De Vito, Corrado ^b   Marzuillo, Carolina ^b   Boccia, Antonio ^b   Villari, Paolo ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Drospirenone; Meta analysis; Oral contraceptives; Venous thromboembolism.

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CYPROTERONE; DESOGESTREL; DROSPIRENONE; ESTROGEN; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

COHORT ANALYSIS; DRUG SAFETY; GENE MUTATION; HUMAN; IDIOPATHIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

EID: 84988305159     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11598050-000000000-00000     Document Type: Article

References (91)

1. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 2010 Aug; 23 (29): 1-44
2. World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1998; 877: i-vii, 1-89
3. Barritt DW, Jordan WM. Clinical features of pulmonary embolism. Lancet 1961 Apr 8; I (7180): 729-32
4. Poulter NR, Chang CL, Farley TMM, et al. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995 Dec 16; 346 (8990): 1575-82 (Pubitemid 26001838)
5. Spitzer WO, Lewis MA, Heinenmann LA, et al. Thirdgeneration oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996 Jan 13; 312 (7023): 83-8
6. Bloemenkamp KW, Rosendaal FR, Büller HR, et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999 Jan 11; 159 (1): 65-70 (Pubitemid 29044121)
7. Farmer RDT, Lawrenson RA, Todd J-C, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000 Jun; 49 (6): 580-90 (Pubitemid 30326558)
8. Lidegaard Ø, Lokkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009 Aug 13; 339: b2890
9. van Hylckama V, Helmerhost FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009 Aug 13; 339: b2921
10. Heinemann LAJ, Lewis MA, Assmann A, et al. Casecontrol studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraception 2002 Mar; 65 (3): 207-14 (Pubitemid 34258541)
11. Mohllajee AP, Curtisa KM, Martins SL, et al. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 2006 Feb; 73 (2): 166-78 (Pubitemid 43087766)
12. Vandenbroucke JP, Rosing J, BloemenkampKW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001 May 17; 344 (20): 1527-35 (Pubitemid 32429213)
13. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and costeffectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006 Apr; 10 (11): 1-110
14. Koster T, Small RA, Rosendaal FR, et al. Oral contraceptives and venous thromboembolism: a quantitative discussion of uncertainties. J InternMed 1995 Jul; 238 (1): 31-7
15. Pharmacy Times. Top 200 prescription drugs of 2009 [online]. Available from URL: http://www.pharmacytimes.com/issue/pharmacy/2010/May2010/ RxFocusTopDrugs-0510 [Accessed 2011 Feb 9]
16. Deeks JJ, Higgins JPT, Altman DG. Analysing and presenting results. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.6. Section 8. The Cochrane Collaboration 2006 [online]. Available from URL: http://www.cochrane.org/sites/default/files/uploads/ Handbook4.2.6Sep2006.pdf [Accessed 2011 Dec 29]
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88 (Pubitemid 17189972)
18. Orsini N. P2CI: Statamodule to calculate confidence limits of a regression coefficient from the p-value. Boston College Department of Economics: Statistical Software Components, 2005. S449101 [online]. Available from URL: http://ideas.repec. org/c/boc/bocode/s449101.html [Accessed 2010 May 5]
19. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001 Jul 14; 323 (7304): 101-5 (Pubitemid 32681979)
20. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ 1998 Jan 10; 316 (7125): 140-4 (Pubitemid 28121116)
21. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997 Sep 13; 315 (7109): 629-34 (Pubitemid 27387172)
22. Vandenbroucke JP, Koster T, Briët E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994 Nov 26; 344 (8935): 1453-7 (Pubitemid 24351698)
23. Khader YS, Rice J, John L, et al. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception 2003 Jul; 68 (1): 11-7 (Pubitemid 37271985)
24. Manzoli L, Villari P, Pirone GM, et al. Marital status and mortality in the elderly: a systematic review and metaanalysis. Soc Sci Med 2007 Jan; 64 (1): 77-94 (Pubitemid 44750327)
25. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. Thromb Haemost 2009 Aug; 102 (2): 360-70
26. Lewis MA, Heinemann LAJ, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women [published erratum appears in Contraception 1996 Aug; 54 (2): 121]. Contraception 1996 Jul; 54 (1): 5-13 (Pubitemid 26230794)
27. Lidegaard Ø, EdstromB, Kreiner S. Oral contraceptives and venous thromboembolism: a case-control study. Contraception 1998 May; 57 (5): 291-301
28. Lewis MA. The Transnational Study on Oral Contraceptives and the Health of Young Women: methods, results, new analyses and the healthy user effect. Hum Reprod Update 1999 Nov-Dec; 5 (6): 707-20 (Pubitemid 30034893)
29. Spitzer WO, Faith JM, MacRae KD. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod 2002 Sep; 17 (9): 2307-14 (Pubitemid 35021451)
30. Thompson SG, Sharp SJ. Explaining heterogeneity in metaanalysis: a comparison of methods. Stat Med 1999 Oct 30; 18 (20): 2693-708 (Pubitemid 29481404)
31. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003 Sep 6; 327 (7414): 557-60 (Pubitemid 37088507)
32. Dinger JC, Heinemann LAJ, Khul-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007 May; 75 (5): 344-54 (Pubitemid 46551071)
33. Royal College of Practitioners. Oral contraception, venous thrombosis, and varicose veins. J R Coll Gen Pract 1978 Jul; 28 (192): 393-9
34. Porter JB, Hunter JR, Danielson DA, et al. Oral contraceptives and nonfatal vascular disease: recent experience. Obstet Gynecol 1982 Mar; 59 (3): 299-302 (Pubitemid 12176945)
35. Porter JB, Hunter JR, Jick H, et al. Oral contraceptives and nonfatal cardiovascular disease. Obstet Gynecol 1985 Jul; 66 (1): 1-4 (Pubitemid 15047372)
36. Vessey M, Mant D, Smith A, et al. Oral contraceptives and venous thromboembolism: findings in a large prospective study [letter]. BMJ (Clin Res Ed) 1986 Feb 22; 292 (6519): 526 (Pubitemid 16126103)
37. Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991 Jan; 133 (1): 32-7
38. Farmer RDT, Preston TD. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J Obstet Gynaecol 1995; 15: 195-200
39. Farmer R. Safety of modern oral contraceptives [letter]. Lancet 1996 Jan 27; 347 (8996): 259
40. Lewis MA, MacRae KD, Kühl-Habichl D, et al. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999 Jun; 14 (6): 1493-9 (Pubitemid 29265441)
41. Burnhill MS. The use of a large-scale surveillance system in planned parenthood federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives. Int J Fertil Womens Med 1999 Jan-Feb; 44 (1): 19-30 (Pubitemid 29136417)
42. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999 Jul 10; 354 (9173): 127-8 (Pubitemid 29313151)
43. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999 Nov 6; 354 (9190): 1610-1 (Pubitemid 29515957)
44. Santamaria A, Mateo J, Oliver A, et al. Risk of thrombosis associated with oral contraceptives in women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G2021A mutation of the prothrombin gene. Haematologica 2001 Sep; 86 (9): 965-71 (Pubitemid 32937706)
45. Hedenmalm K, Samuelsson E, Spigset O. Pulmonary embolism associated with combined oral contraceptives: reporting incidences and potential isk factors for a fatal outcome. Acta Obstet Gynecol Scand 2004 Jun; 83 (6): 576-85 (Pubitemid 38703553)
46. Seeger JD, Loughlin J, Eng PM, et al. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007 Sep; 110 (3): 587-93 (Pubitemid 47359582)
47. Royal College of Practitioners. Oral contraception and thrombo-embolic disease. J R Coll Gen Pract 1967 May; 13 (3): 267-79
48. Sartwell PE, Masi AT, Arthes FG, et al. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol 1969 Nov; 90 (5): 365-80
49. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. BMJ 1969 Jun 14; 2 (5658): 651-7
50. Boston Collaborative Drug Surveillance Programme. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall-bladder disease, and breast tumours. Lancet 1973 Jun 23; 1 (7817): 1399-404
51. Greenblatt DJ. A retrospective case-control study of diseases associated with oral contraceptive use. Am Heart J 1975 May; 89 (5): 677-8
52. Petitti DB, Wingerd J, Pellegrin F, et al. Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease. Am J Epidemiol 1978 Dec; 108 (6): 480-5 (Pubitemid 9147731)
53. Maguire MG, Tonascia J, Sartwell PE, et al. Increased risk of thrombosis due to oral contraceptives: a further report. Am J Epidemiol 1979 Aug; 110 (2): 188-95 (Pubitemid 10209702)
54. Helmrich SP, Rosenberg L, Kaufman DW, et al. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987 Jan; 69 (1): 91-5 (Pubitemid 17205388)
55. World Health Organization Collaborative Study. Cardiovascular disease and use of oral contraceptives. Bull World Health Organ 1989; 67: 417-23
56. Thorogood M, Mann J, Murphy M, et al. Risk factors for fatal venous thromboembolism in young women: a casecontrol study. Int J Epidemiol 1992 Feb; 21 (1): 48-52
57. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deepvein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995 Dec 16; 346 (8990): 1593-6 (Pubitemid 26001841)
58. Farley TMM, Meirik O, Chang CL, et al. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995 Dec 16; 346 (8990): 1582-8 (Pubitemid 26001839)
59. Lewis MA, Heinemann LAJ, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996 Jul; 54 (1): 5-13 (Pubitemid 26230794)
60. Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997 Sep; 56 (3): 141-6 (Pubitemid 27450823)
61. Andersen BS, Olsen J, Nielsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998 Jan; 79 (1): 28-31 (Pubitemid 28037051)
62. Bennet L, Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med 1998 Jul; 244 (1): 27-32 (Pubitemid 28322602)
63. Farmer RDT, Todd J-C, Lewis MA, et al. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998 Feb; 57 (2): 67-70 (Pubitemid 28208475)
64. Lidegaard Ø. Thrombotic diseases in young women and the influence of oral contraceptives. Am J Obstet Gynecol 1998 Sep; 179 (3 Pt 2): S62-7 (Pubitemid 28447224)
65. Martinelli I, Taioli E, Bucciarelli P, et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999 Mar; 19 (3): 700-3 (Pubitemid 29135174)
66. Todd J-C, Lawrenson R, Farmer RDT, et al. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Hum Reprod 1999 Jun; 14 (6): 1500-5 (Pubitemid 29265442)
67. Aznar J, VayáA, EstellésA, et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica 2000 Dec; 85 (12): 1271-6 (Pubitemid 32063697)
68. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000 Jan 10; 160 (1): 49-52 (Pubitemid 30040972)
69. Jick H, Kaye JA, Vasilakis-Scaramozza C, et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000 Nov 11; 321 (7270): 1190-5
70. Parkin L, Skegg DCG, Wilson M, et al. Oral contraceptives and fatal pulmonary embolism. Lancet 2000 Jun 17; 355 (9221): 2133-4 (Pubitemid 30364664)
71. Spannagl M, Heinemann LAJ, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism? Eur J Contracept Reprod Health Care 2000 Jun; 5 (2): 105-12
72. Suissa S, Spitzer WO, Rainville B, et al. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000 Apr; 15 (4): 817-21 (Pubitemid 30192729)
73. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3240 controls [published erratum appears in Thromb Haemost 2001 Dec; 86 (6): 1598]. Thromb Haemost 2001 Sep; 86 (3): 809-16 (Pubitemid 32834190)
74. Legnani C, Palareti G, Guazzaloca G, et al. Venous thromboembolism in young women. Eur Heart J 2002 Jun; 23 (12): 984-90
75. Sidney S, Petitti DB, Soff GA, et al. Venous thromboembolic disease in users of low-estrogen combined estrogenprogestin oral contraceptives. Contraception 2004 Jul; 70 (1): 3-10 (Pubitemid 38781972)
76. Jick SS, Kaye JA, Russmann S, et al. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006 Jun; 73 (6): 566-70
77. Pomp ER, Rosendaal FR, Doggen CJM. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008 Feb; 83 (2): 97-102
78. Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a metaanalysis and formal sensitivity analysis. Contraception 2001 Aug; 64 (2): 125-33 (Pubitemid 33042599)
79. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: metaanalysis. BMJ 2001 Jul 21; 323 (7305): 131-4 (Pubitemid 32678382)
80. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011; 340: d2151
81. Parkin L, Sharples K, Hernandez RK, et al. Risk of thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 340: d2139
82. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 2000 Jul 5; 284 (1): 72-8 (Pubitemid 30445664)
83. Chan WS, Ray J, Wai EK, et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004Apr 12; 164 (7): 741-7 (Pubitemid 38478696)
84. Baillargeon JP, McClish DK, Essah PA, et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005 Jul; 90 (7): 3863-70 (Pubitemid 41058144)
85. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011; 8 (5): e1001026
86. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007 Apr; 5 (4): 692-9 (Pubitemid 46563566)
87. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995 Feb 18; 310 (6977): 452-4
88. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991 May; 151 (5): 933-8
89. Samuelsson E, Hedenmalm K, Persson I. Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives: an approach to specifying rates. Eur J Epidemiol 2005; 20 (6): 509-16 (Pubitemid 40933928)
90. Hoyert DL. Maternal mortality and related concepts. Vital Health Stat 2007 Feb 3; (33): 1-13
91. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization, 2004